NMD Pharma Initiates an Observational Pilot Study Investigating the Effects of Sarcopenia on Neuromuscular Transmission in Older Adults
NMD Pharma is developing first-in-class small molecule inhibitors of the muscle specific chloride ion channel, the ClC-1 ion channel and has already demonstrated that ClC-1 inhibition can strengthen neuromuscular transmission and ultimately skeletal muscle function.
- NMD Pharma is developing first-in-class small molecule inhibitors of the muscle specific chloride ion channel, the ClC-1 ion channel and has already demonstrated that ClC-1 inhibition can strengthen neuromuscular transmission and ultimately skeletal muscle function.
- This study is intended to establish whether NMJ transmission deficits occur in sarcopenic individuals, and to investigate whether these deficits correlate with reduced physical performance.
- Thomas Holm Pedersen, Chief Executive Officer of NMD Pharma, said: This is the first clinical study that NMD Pharma has coordinated in older adults with sarcopenia.
- We are grateful to the world-leading clinical teams in Ohio, and their prospective study participants, for making this study possible.